Skip to main content
SpringerLink
Log in

Hyperthyroidism

  • Chapter
Challenging Cases in Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 196 Accesses

Abstract

A 54-yr-old African-American woman was seen at an urgent care facility because of the recent development of palpitations. When examined, she was noted to have a pulse of 100 bpm. Her thyroid was normal in size, and the rest of the physical examination was normal. Thyroid function tests were as follows: T4 14 μg/dL, T3RU 43% (25–35), thyroid-stimulating hormone (TSH) 1.6 mU/L. These results were interpreted as indicating that the patient was euthyroid, and she was started on a (β-blocker for symptomatic relief. However, one of the physicians in the urgent care center felt that the thyroid function tests were somewhat inconsistent, and called for further advice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17: 610–638.

    PubMed  CAS  Google Scholar 

  2. Smallridge RC. Thyrotropin-secreting pituitary tumors. Endocrinol Metab Clin North Am 1987; 16: 765–792.

    PubMed  CAS  Google Scholar 

  3. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996; 81: 3084–3090.

    Article  PubMed  CAS  Google Scholar 

  4. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999; 84: 476–486.

    Article  PubMed  CAS  Google Scholar 

  5. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 1987; 317: 12–17.

    Article  PubMed  CAS  Google Scholar 

  6. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993; 119: 236–240.

    PubMed  CAS  Google Scholar 

  7. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 1994; 40: 421–428.

    Article  CAS  Google Scholar 

  8. Burger, A, Dinichert, D, Nicod, P, Jenny, M, Lemarchand-Beraud, T, Vallotton, MB. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin: A drug influencing peripheral metabolism of thyroid hormones. J Clin Invest 1976; 58: 255–259.

    Article  PubMed  CAS  Google Scholar 

  9. Nademanee K, Singh BN, Callahan B, Hendrickson JA, Hershman JM. Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol 1986; 58: 981–986.

    Article  PubMed  CAS  Google Scholar 

  10. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126: 63–73.

    PubMed  CAS  Google Scholar 

  11. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee C. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101: 28–34.

    PubMed  CAS  Google Scholar 

  12. Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C, Braverman LE, Pinchera A. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology 1994; 134: 2277–2282.

    Article  PubMed  CAS  Google Scholar 

  13. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996; 81: 2930–2933.

    Article  PubMed  CAS  Google Scholar 

  14. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507–511.

    Article  PubMed  CAS  Google Scholar 

  15. Brennan MD, van Heerden JA, Carney JA. Amiodarone-associated thyrotoxicosis (AAT): experience with surgical management. Surgery 1987; 102: 1062–1067.

    PubMed  CAS  Google Scholar 

  16. Martino E, Bartalena L, Mariotti S, Aghini-Lombardi F, Ceccarelli C, Lippi F, Piga M, Loviselli A, Braverman L, Safran M. Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 1988; 119: 167–173.

    CAS  Google Scholar 

  17. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E. Serum interleukin6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994; 78: 423–427.

    Article  PubMed  CAS  Google Scholar 

  18. Bauters C, D’Herbomez M, Nocaudie M, Decoulx M, Marchandise X, Wemeau JL. Interleukin-6 and thyroid radioactive iodine uptake in patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 1999; 22: 94 (abstract).

    Google Scholar 

  19. Bogazzi F, Bartalena L, Brogioni S, Mazzeo S, Vitti P, Burelli A, Bartolozzi C, Martino E. Color flow doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997; 7: 541–545.

    Article  PubMed  CAS  Google Scholar 

  20. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986; 62: 563–568.

    Article  PubMed  CAS  Google Scholar 

  21. Harjai KJ, Licata AA. Amiodarone-Induced Hyperthyroidism. PACE 1996; 19: 1548–1554

    Article  PubMed  CAS  Google Scholar 

  22. Roti E, Minelli R, Gardini E, Bianconi L, Braverman LE. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. Arch Intern Med 1993; 153: 886–892.

    Article  PubMed  CAS  Google Scholar 

  23. Seminara S, Daniels G. Amiodarone and the thyroid. Endoc Pract 1998; 4: 48–57.

    Article  CAS  Google Scholar 

  24. Dickstein G, Shechner C, Adawi F, Kaplan J, Baron E, Ish-Shalom S. Lithium treatment in amiodaroneinduced thyrotoxicosis. Am J Med 1997; 102: 454–458.

    Article  PubMed  CAS  Google Scholar 

  25. Mulligan, DC, McHenry, CR, Kinney, W, Esselstyn, CB. Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. Surgery 1993; 114: 1114–1119.

    PubMed  CAS  Google Scholar 

  26. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Ann Intern Med 1983; 98: 26–29.

    PubMed  CAS  Google Scholar 

  27. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis: the usefulness of routine white blood cell count monitoring. Arch Int Med 1990; 150: 621–624.

    Article  CAS  Google Scholar 

  28. Sheng WH, Hung CC, Chen YC, Fang CT, Hsieh SM, Chang SC, Hsieh WC. Antithyroid-drug-induced agranulocytosis and infectious complications. Q J Med 1999; 92: 455–461.

    Article  CAS  Google Scholar 

  29. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79: 366–371.

    Article  PubMed  CAS  Google Scholar 

  30. Somogyi A, Rosta A, Lang I, Werling K. Treatment of drug-induced bone marrow suppression with recombinant human granulocyte/monocyte colony stimulating factor. Adverse Drug Reac Toxicol Rev 1996; 15: 119–124.

    CAS  Google Scholar 

  31. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9: 29–31.

    Article  PubMed  CAS  Google Scholar 

  32. Tamai H, Mukuta T, Matsubayashi S, et al. Treatment of methimazole-induced recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 1993; 77: 1356–1360.

    Article  PubMed  CAS  Google Scholar 

  33. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1990; 70: 1518–1524.

    Article  PubMed  CAS  Google Scholar 

  34. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985; 60: 1019–1024.

    Article  PubMed  CAS  Google Scholar 

  35. Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours of propylthiouracil in the treatment of hyperthyroidism. South Med J 1995; 88: 973–976.

    Article  PubMed  CAS  Google Scholar 

  36. Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves’ disease. J Clin Endocrinol Metab 1986; 63: 102–106.

    Article  PubMed  CAS  Google Scholar 

  37. Rivkees SA, Sklar C, Freemark M. The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83: 3767–3776.

    Article  PubMed  CAS  Google Scholar 

  38. Holm LE, Lundell G, Dahlqvist I, Israelsson A. Cure rate after 1311 therapy for hyperthyroidism. Acta Radiol Oncol 1981; 20: 161–166.

    Article  PubMed  CAS  Google Scholar 

  39. Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves’ patients treated with radio-iodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83: 40–46.

    Article  PubMed  CAS  Google Scholar 

  40. Imseis RE, VanMiddlesworth L, Massie JD, Bush Ai, VanMiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of Iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 685–687.

    Article  PubMed  CAS  Google Scholar 

  41. Tallstedt L, Lundell G, Toning O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992; 326: 1733–1738.

    Article  PubMed  CAS  Google Scholar 

  42. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338: 73–78.

    Article  PubMed  CAS  Google Scholar 

  43. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Int Med 1998; 129: 632–635.

    PubMed  CAS  Google Scholar 

  44. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994; 130: 494–497.

    Article  PubMed  CAS  Google Scholar 

  45. Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349–1352.

    Article  PubMed  CAS  Google Scholar 

  46. Cooper DS. The side-effects of antithyroid drugs. The Endocrinologist 1999; 9: 457–467.

    Article  Google Scholar 

  47. Schimmel M, Utiger RD. Acute effect of inorganic iodide after 1311 therapy for hyperthyroidism. Clin Endocrinol 1977; 6: 329–332.

    Article  CAS  Google Scholar 

  48. Ross DS, Daniels GH, DeStefano P, et al. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 250–253.

    Article  PubMed  CAS  Google Scholar 

  49. Braga M, Cooper DS. Oral cholecystographic agents and the thyroid. J Clin Endocrinol Metab 2001; 86: 2354–2359.

    Article  Google Scholar 

  50. Gomez N, Gomez JM, Ortiz A, et al. Transient hypothyroidism after Iodine-131 therapy for Graves’ disease. J Nucl Med 1995; 36: 1539–542.

    PubMed  CAS  Google Scholar 

  51. Sawers JSA, Toft AD, Irvine WJ, Brown NS, Seth J. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis. J Clin Endocrinol Metab 1980; 50: 226–229.

    Article  PubMed  CAS  Google Scholar 

  52. Toning O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective randomized study. J Clin Endocrinol Metab 1996; 81: 2986–2993.

    Article  Google Scholar 

  53. Kahaly GJ, Nieswandt J, Mohr-Kahaly S. Cardiac risks of hyperthyroidism in the elderly. Thyroid 1998; 8: 1165–1169.

    Article  PubMed  CAS  Google Scholar 

  54. Jodar E, Munoz-Torres M, Escobar-Jimenez F, Quesada-Charneco M, Lund del Castillo JD. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol 1997; 47: 279–285.

    Article  CAS  Google Scholar 

  55. Feely J, Crooks J, Forrest AL, et al. Propranolol in the surgical treatment of hyperthyroidism, including severely thyrotoxic patients. Br J Surg 1981; 68: 865–869.

    Article  PubMed  CAS  Google Scholar 

  56. Baeza A, Aguayo M, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol 1991; 35: 439–442.

    Article  CAS  Google Scholar 

  57. Coyle PJ, Mitchell JE. Thyroidectomy: is Lugol’s iodine necessary? Ann R Coll Surg Engl 1982; 64: 334–345.

    PubMed  CAS  Google Scholar 

  58. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320–330.

    Article  PubMed  CAS  Google Scholar 

  59. Sugino K, Mimura T, Ozaki O, et al. Management of recurrent hyperthyroidism in patients with Graves’ disease treated by subtotal thyroidectomy. J Endocrinol Invest 1995; 18: 415–419.

    PubMed  CAS  Google Scholar 

  60. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Endocrinol Metab Clin North Am 1993; 22: 263–277.

    PubMed  CAS  Google Scholar 

  61. Brooks MH, Waldstein SS. Free thyroxine concentrations in thyroid storm. Ann Intern Med 1980; 93: 694697.

    Google Scholar 

  62. Andrade VL, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 4012–4016.

    Article  PubMed  CAS  Google Scholar 

  63. Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves’ disease. Clin Endocrinol 1988; 28: 305–314.

    Article  CAS  Google Scholar 

Download references

Authors
  1. David S. Cooper MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, IL, USA

    Mark E. Molitch MD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cooper, D.S. (2002). Hyperthyroidism. In: Molitch, M.E. (eds) Challenging Cases in Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-277-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-277-7_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-249-0

  • Online ISBN: 978-1-59259-277-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation